Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[1] Immune checkpoint inhibitors for hepatocellular carcinoma
El Dika, Imane
Khalil, Danny N.
Abou-Alfa, Ghassan K.
CANCER, 2019, 125 (19) : 3312 - 3319
[2] Immune checkpoint inhibitors for hepatocellular carcinoma
Jensen, Christopher E.
Loaiza-Bonilla, Arturo
Bonilla-Reyes, Paula A.
HEPATIC ONCOLOGY, 2016, 3 (03) : 201 - 211
[3] Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma
Ruff, Samantha M.
Pawlik, Timothy M.
HEPATOMA RESEARCH, 2024, 10
[4] Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review
Tian, Chunhong
Yu, Yifan
Wang, Yuqing
Yang, Lunwei
Tang, Ying
Yu, Chengyang
Feng, Gaofei
Zheng, Dayong
Wang, Xiongwen
FRONTIERS IN IMMUNOLOGY, 2024, 15
[5] Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma
Kalasekar, Sharanya Maanasi
Garrido-Laguna, Ignacio
Evason, Kimberley Jane
HEPATOLOGY, 2021, 73 (06) : 2591 - 2593
[6] Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Abd El Aziz, Mohamed A.
Facciorusso, Antonio
Nayfeh, Tarek
Saadi, Samer
Elnaggar, Mohamed
Cotsoglou, Christian
Sacco, Rodolfo
VACCINES, 2020, 8 (04) : 1 - 19
[7] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Akbulut, Zeynep
Aru, Basak
Aydin, Furkan
Demirel, Gulderen Yanikkaya
FRONTIERS IN IMMUNOLOGY, 2024, 15
[8] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
van Doorn, Diederick J.
Takkenberg, Robert Bart
Klumpen, Heinz-Josef
PHARMACEUTICALS, 2021, 14 (01) : 1 - 23
[9] Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
Rizzo, Alessandro
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) : 333 - 335
[10] Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Zhao, Mei
Chen, Shanwen
Li, Conggui
Du, Yingying
Li, Ping
CANCERS, 2023, 15 (03)

← 1 2 3 4 5 →